Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study

被引:382
|
作者
Souery, Daniel
Oswald, Pierre
Massat, Isabelle
Bailer, Ursula
Bollen, Joseph
Demyttenaere, Koen
Kasper, Siegfried
Lecrubier, Yves
Montgomery, Stuart
Serretti, Alessandro
Zohar, Joseph
Mendlewicz, Julien
机构
[1] Univ Libre Bruxelles, Hop Erasme, Psychiat Serv, Dept Psychiat, B-1070 Brussels, Belgium
[2] Sint Truiden Psychiat Ctr, Dept Psychiat, St Truiden, Belgium
[3] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium
[4] Med Univ Vienna, Dept Gen Psychiat, Vienna, Austria
[5] Hop La Pitie Salpetriere, INSERM U302, Paris, France
[6] Univ London Imperial Coll Sci Technol & Med, London, England
[7] Ist Sci San Raffaele, Dept Psychiat, Milan, Italy
[8] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
关键词
D O I
10.4088/JCP.v68n0713
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objectives: Very few studies have investigated clinical features associated with treatment-resistant depression (TRD) defined as failure of at least 2 consecutive antidepressant trials. The primary objective of this multicenter study was to identify specific clinical and demographic factors associated with TRD in a large sample of patients with major depressive episodes that failed to reach response or remission after at least 2 consecutive adequate antidepressant treatments. Method: A total of 702 patients with DSM-IV major depressive disorder, recruited from January 2000 to February 2004, were included in the analysis. Among them, 346 patients were considered as nonresistant. The remaining 356 patients were considered as resistant, with a 17-item Hamilton Rating Scale for Depression score remaining greater than or equal to 17 after 2 consecutive adequate antidepressant trials. Cox regression models were used to examine the association between individual clinical variables and TRD. Results: Among the clinical features investigated, I I variables were found to be associated with TRD. We found anxiety comorbidity (p <.001, odds ratio [OR] = 2.6), comorbid panic disorder (p <.001, OR = 3.2) and social phobia (p =.008, OR = 2. 1), personality disorder (p =.049, OR = 1.7), suicidal risk (p =.001, OR = 2.2), severity (p =.001, OR = 1.7), melancholia (p =.018, OR 1.5), a number of hospitalizations > I (p=.003, OR 1.6), recurrent episodes (p =.009, OR 1.5), early Age at onset (p =.009, OR = 2.0), and nonresponse to the first antidepressant received lifetime (p =.019, OR = 1.6) to be the factors associated with TRD. Conclusions: Our findings provide a set of 11 relevant clinical variables associated with treatment resistance in major depressive disorder that can be explored at the clinical level. The statistical model used in this analysis allowed for a hierarchy of these variables (based on the OR) showing that comorbid anxiety disorder is the most powerful clinical factor associated with TRD.
引用
收藏
页码:1062 / 1070
页数:9
相关论文
共 50 条
  • [1] Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study
    Dold, Markus
    Bartova, Lucie
    Souery, Daniel
    Mendlewicz, Julien
    Serretti, Alessandro
    Porcelli, Stefano
    Zohar, Joseph
    Montgomery, Stuart
    Kasper, Siegfried
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 91 : 1 - 13
  • [2] Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study
    Fugger, Gernot
    Dold, Markus
    Bartova, Lucie
    Kautzky, Alexander
    Souery, Daniel
    Mendlewicz, Julien
    Serretti, Alessandro
    Zohar, Joseph
    Montgomery, Stuart
    Frey, Richard
    Kasper, Siegfried
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 (06) : 777 - 785
  • [3] Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study
    Dold, Markus
    Bartova, Lucie
    Fugger, Gernot
    Mitschek, Marleen Margret Mignon
    Kautzky, Alexander
    Frey, Richard
    Montgomery, Stuart
    Zohar, Joseph
    Mendlewicz, Julien
    Souery, Daniel
    Fabbri, Chiara
    Serretti, Alessandro
    Kasper, Siegfried
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 41 : 70 - 80
  • [4] Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study
    Dold, Markus
    Bartova, Lucie
    Kautzky, Alexander
    Serretti, Alessandro
    Porcelli, Stefano
    Souery, Daniel
    Mendlewicz, Julien
    Montgomery, Stuart
    Zohar, Joseph
    Kasper, Siegfried
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 (12) : 1305 - 1313
  • [5] The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study
    Dold, Markus
    Bartova, Lucie
    Kautzky, Alexander
    Souery, Daniel
    Mendlewicz, Julien
    Serretti, Alessandro
    Porcelli, Stefano
    Zohar, Joseph
    Montgomery, Stuart
    Kasper, Siegfried
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (07) : 625 - 632
  • [6] Clinical Significance of the Number of Depressive Symptoms in Major Depressive Disorder: Results from the CRESCEND Study
    Park, Seon-Cheol
    Sakong, Jeongkyu
    Koo, Bon Hoon
    Kim, Jae-Min
    Jun, Tae-Youn
    Lee, Min-Soo
    Kim, Jung-Bum
    Yim, Hyeon-Woo
    Park, Yong Chon
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2016, 31 (04) : 617 - 622
  • [7] The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder - A European Multicenter Study
    Schosser, A.
    Calati, R.
    Serretti, A.
    Massat, I.
    Kocabas, N. A.
    Papageorgiou, K.
    Linotte, S.
    Mendlewicz, J.
    Souery, D.
    Zohar, J.
    Juven-Wetzler, A.
    Montgomery, S.
    Kasper, S.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 (04) : 259 - 266
  • [8] THE IMPACT OF BDNF GENE POLYMORPHISMS ON SUICIDALITY IN TREATMENT RESISTANT MAJOR DEPRESSIVE DISORDER - A EUROPEAN MULTICENTER STUDY
    Schosser, A.
    Calati, R.
    Serretti, A.
    Massat, I.
    Papageorgiou, K.
    Linotte, S.
    Mendlewicz, J.
    Souery, D.
    Zohar, J.
    Montgomery, S.
    Kasper, S.
    [J]. EUROPEAN PSYCHIATRY, 2012, 27
  • [9] The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
    Schosser, Alexandra
    Carlberg, Laura
    Calati, Raffaella
    Serretti, Alessandro
    Massat, Isabel
    Spindelegger, Christoph
    Linotte, Sylvie
    Mendlewicz, Julien
    Souery, Daniel
    Zohar, Joseph
    Montgomery, Stuart
    Kasper, Siegfried
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (10): : 782 - 787
  • [10] Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
    Kautzky, A.
    Dold, M.
    Bartova, L.
    Spies, M.
    Kranz, G. S.
    Souery, D.
    Montgomery, S.
    Mendlewicz, J.
    Zohar, J.
    Fabbri, C.
    Serretti, A.
    Lanzenberger, R.
    Dikeos, D.
    Rujescu, D.
    Kasper, S.
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2019, 139 (01) : 78 - 88